Grufity logo
Grufity logo
DARE

DARE - Dare Bioscience Inc Stock Price, Fair Value and News

$2.12+0.14 (+7.07%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

6/100

DARE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

6/100

DARE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

DARE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DARE Price Action

Last 7 days

8.1%

Last 30 days

-7.8%

Last 90 days

37.9%

Trailing 12 Months

-34.0%

DARE RSI Chart

DARE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

DARE Valuation

Market Cap

28.8M

Price/Earnings (Trailing)

-2.4

Price/Sales (Trailing)

27.98

EV/EBITDA

-0.87

Price/Free Cashflow

-2.84

DARE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

DARE Fundamentals

DARE Revenue

DARE Earnings

Earnings (TTM)

-12.0M

Earnings Growth (Yr)

31.48%

Earnings Growth (Qtr)

-108.08%

DARE Profitability

Operating Margin

71.29%

EBT Margin

-1314.41%

Return on Equity

-1.6K%

Return on Assets

-43.2%

Free Cashflow Yield

-35.19%

DARE Investor Care

Shares Dilution (1Y)

64.51%

Diluted EPS (TTM)

-0.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
20251.8M1.5M1.3M1.0M
20242.6M2.3M2.0M-
2023--11.0M2.8M
2022-12.6M11.8M10.6M
20172.0M2.6M--
2016---799.0K
2014407.0K298.0K189.0K80.0K
2013---516.0K
2012---625.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Dare Bioscience Inc

DARE
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy. The company's Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1, a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
 CEO
 WEBSITEdarebioscience.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES25

Dare Bioscience Inc Frequently Asked Questions

DARE is the stock ticker symbol of Dare Bioscience Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Dare Bioscience Inc is 28.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, DARE's PE ratio (Price to Earnings) is -2.4 and Price to Sales (PS) ratio is 27.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DARE PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Dare Bioscience Inc has provided -0.384 (multiply by 100 for percentage) rate of return.